ULBP2 and breast carcinoma: In breast cancer, miR-20a was found to inhibit the expression of MICA/B and ULBP2 by directly targeting MICA/B and downregulating ULBP2 through inhibition of MAPK/ERK, which ultimately resulted in a decrease in the cytotoxicity of NK cells (87).